Clinical Trials · NCT06737042

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Name: Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Tirzepatide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Gan and Lee Pharmaceuticals, USA
Enrollment: 326
Start date: Feb 2025
Locations: 20 sites, United States
Primary endpoint: Primary Objective

View Tirzepatide compound reference